Margins matter. The moreEnergy (NYSE: NVE ) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders. Healthy margins often separate pretenders from the best stocks in the market. That's why we check up on margins at least once a quarter in this series. I'm looking for the absolute numbers, so I can compare them to current and potential competitors, and any trend that may tell me how strongEnergy's competitive position could be.
Here's the current margin snapshot forEnergy over the trailing 12 months: Gross margin is 54.9%, while operating margin is 26.4% and net margin is 10.8%.
Unfortunately, a look at the most recent numbers doesn't tell us much about whereEnergy has been, or where it's going. A company with rising gross and operating margins often fuels its growth by increasing demand for its products. If it sells more units while keeping costs in check, its profitability increases. Conversely, a company with gross margins that inch downward over time is often losing out to competition, and possibly engaging in a race to the bottom on prices. If it can't make up for this problem by cutting costs -- and most companies can't -- then both the business and its shares face a decidedly bleak outlook.
Top 5 Low Price Companies For 2015: Antares Pharma Inc (ATRS)
Antares Pharma, Inc. (Antares) is a pharma company that focuses on self-injection pharmaceutical products and technologies and topical gel-based products. The Company�� subcutaneous and intramuscular injection technology platforms include Vibex disposable pressure-assisted auto injectors, Vision reusable needle-free injectors, and disposable multi-use pen injectors. In the injector area, it has licensed its reusable needle-free injection device for use with human growth hormone (hGH) to Teva, Ferring Pharmaceuticals BV (Ferring) and JCR Pharmaceuticals Co., Ltd. (JCR), with Teva and Ferring being its two primary customers. The Company has also licensed both disposable auto and pen injection devices to Teva for use in certain fields and territories and is engaged in product development activities for Teva utilizing these devices.
In the gel-based area, it received Food and Drug Administration (FDA) approval in December 2011 for its oxybutynin gel 3% product, Anturol, for the treatment of overactive bladder. Antares also has a licensing agreement with Watson Watson Pharmaceuticals, Inc. (Watson) under which Watson will commercialize its topical oxybutynin gel 3% product in the United States and Canada. Its gel portfolio also includes Elestrin (estradiol gel) in the United States for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. Antares has designed disposable, pressure assisted auto injector devices to address acute medical needs, such as allergic reactions, migraine headaches, acute pain, emesis and other daily therapies.
Pressure Assisted Injection Devices
The Company�� Pressure Assisted Injection Devices consists of three products: reusable needle-free injectors, disposable pressure assisted auto injectors and disposable pen injectors. Reusable needle-free injectors deliver precise medication doses through high-speed, pressurized liquid penetration of the skin without a needle. The injector employs a disposable pl! astic needle-free syringe, which offers liquid medication delivery through an opening that is approximately half the diameter of a standard, 30-gauge needle.
Disposable pressure assisted auto injectors is a technology of controlled pressure delivery of drugs into the body utilizing a spring power source. The Vibex is designed to provide fast subcutaneous or intramuscular injections of up to 0.5ml with minimal discomfort and improved convenience in conjunction with the enhanced safety of a shielded needle. Disposable pen injectors are needle-based devices designed to deliver multiple injections from multi-dose drug cartridges. The devices contain mechanisms that specify the dose to be delivered by defining the amount of movement by the stopper in the cartridge with each device actuation.
The Vision/Tjet has been sold for use in more than 30 countries to deliver either insulin or hGH. The product features a reusable, spring-based power source and disposable needle-free syringe, which acts as the pathway for the injectable drug through the skin and allows for viewing of the medication dose prior to injection. The product is also reusable, with each device designed to last for approximately 3,000 injections (or approximately two years) while the needle-free syringe, when used with insulin or hGH, is disposable after approximately one week when used by a single patient for injecting from multi-dose vials. The Vision/Tjet administers injectables by using a spring to push the active ingredient in solution or suspension through a micro-fine opening in the needle-free syringe. The opening is approximately half the diameter of a 30-gauge needle. The Vision/Tjet is primarily used in the United States, Europe, Asia and Japan.
Antares has designed disposable, pressure assisted auto injector devices to address acute medical needs, such as allergic reactions, migraine headaches, acute pain, emesis and other daily therapies. Its Vibex disposable product combines a low-energy, spr! ing-based! power source with a hidden needle, which delivers up to 0.5ml of the needed drug solution subcutaneously or intramuscularly. Antares is also developing a Vibex MTX auto injector for delivery of methotrexate for treatment of rheumatoid arthritis. The Company�� multi use, disposable pen injector complements its portfolio of single-use pressure assisted auto injector devices. The disposable pen injector device is designed to deliver drugs by injection through needles from multi- dose cartridges. The disposable pen is in the stage of development where devices are being used in clinical evaluations.
Transdermal Products
The Company�� ATD system penetrates the skin to deliver a variety of treatments. The gels consist of a hydro-alcoholic base, including a combination of permeation enhancers. Products being developed/ commercialized include Anturol, Elestrin and Nestragel. Elestrin is a transdermal estradiol gel for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. Its other injectable drugs that are presently self-administered and may be suitable for injection with its systems include therapies for the prevention of blood clots and treatments for multiple sclerosis, migraine headaches, inflammatory diseases, impotence, infertility, acquired immune deficiency symdrome (AIDS) and hepatitis.
The Company competes with Ypsomed AG, SHL Group AB, OwenMumford Ltd., West Pharmaceuticals, Becton Dickinson, Haselmeir GmbH, Elcam Medical, Vetter Pharma, Bioject Medical Technologies Inc., The Medical House PLC, Watson, Abbott, Eli Lilly, Auxillium, Inc., Endo Pharmaceuticals, Teva, Mylan, Roxane, Bedford Labs, APP Pharmaceuticals, Hospira, Pfizer, GSK/Astellas, Warner Chilcott and Allergan.
Advisors' Opinion:- [By Keith Speights]
Antares Pharma (NASDAQ: ATRS ) announced its first-quarter results �Wednesday morning but failed to impress the market. Shares were down around 3% in midday trading. Here are the highlights from the company's results.
- [By Bryan Murphy]
This is NOT a judgment call on the drug. This isn't a judgment call on the company either. This is a judgment call on how emotional and distracted traders can get from time to time, and we only have to look at Antares Pharma Inc. (NASDAQ:ATRS), Avanir Pharmaceuticals Inc. (NASDAQ:AVNR), and VIVUS, Inc. (NASDAQ:VVUS) to see how drinking the proverbial Kool-Aid ultimately punished anyone who bought rather than sold ATRS, VVUS, and AVNR right when the news seemed to incredibly encouraging.
Hot Rising Companies To Watch For 2014: ICL Israel Chemicals Ltd (ICL)
ICL Israel Chemicals Ltd (ICL) is an Israel-based company, engaged in the fertilizer and specialty chemical sectors. The company operates in three segments: Fertilizers, Industrial Products, and Performance Products. The Fertilizers segment is engaged in the production of standard, granular, fine red and white potash from three sources, as well as in the production of phosphates, such as phosphate rock, phosphoric acid, fertilizers and animal feed addictives. The Industrial Products segment produces flame retardants, such as brominates and organ phosphorus; elemental bromine, and other chemicals. In addition the Performance Products segment produces specialty phosphates, such as technical, food grade and electronic grade phosphoric acid, phosphate salts, food additives and wildfire safety products, as well as alumina and other chemicals. Advisors' Opinion:- [By Gwen Ackerman]
Israel Chemicals Ltd. (ICL), the fourth-largest potash producer in the world by sales, is weighing on the Tel Aviv benchmark stock index on concern the government will exact higher royalties amid a global oversupply.
- [By Claudia Maedler]
In Israel, the TA-25 Index (TA-25) gained 1.9 percent at the close in Tel Aviv as Israel Corp. jumped 9 percent, the most since July 2009, to 1,755 shekels. The shares soared along with those of its Israel Chemicals Ltd. (ICL) unit, which advanced 6.4 percent on speculation that a possible change in ownership of Russian potash producer OAO Uralkali could help stabilize prices of the crop nutrient.
Hot Rising Companies To Watch For 2014: VolitionRX Ltd (VNRX)
VolitionRX Limited, formerly Standard Capital Corporation, incorporated on September 24, 1998, through its wholly owned subsidiary Singapore Volition Pte Limited (Volition), is a life sciences company focused on developing blood-based diagnostic tests. As of October 12, 2011, Volition was developing a range of blood-based epigenetic cancer screening tests, which will be released for research then clinical use in Europe, North America and globally. The tests will enable doctors to screen for the general presence of cancer in the body with a single blood test, and investigate, which cancer is present in many of those cancer positive patients using a panel of tests. On October 6, 2011, the Company announced the closure of the share exchange agreement with the Company. On October 6, 2011, Volition became a wholly owned subsidiary of the Company.
Volition�� HyperGenomics technology will determine specific epigenetic signatures from cancer biopsies. The HyperGenomics range of tests will be used as a second line once cancer has been diagnosed, to determine the specific subtype of disease and to help decide the most appropriate therapy. Volition is developing a non-invasive blood test for endometriosis, based on its Nucleosomics technology.
Advisors' Opinion:- [By Peter Graham]
At the end of last week, small cap stocks Senesco Technologies, Inc (OTCBB: SNTI), VolitionRX Ltd (OTCMKTS: VNRX) and Micromem Technologies Inc (OTCBB: MMTIF) were all trending upwards ��ending up 13.65%, 8.73% and 7.61%, respectively, on Friday. However, it�� a new trading week with the last two trading days for the year. So what direction will these three small caps head in for the end of this year and into next year? Here is a quick look to help you decide on a trading or investment strategy:
Hot Rising Companies To Watch For 2014: Vornado Realty Trust(VNO)
Vornado Realty Trust is a privately owned real estate investment trust. The trust engages in investment, ownership, and management of commercial real estate. It invests in the real estate markets of United States. The trust primarily invests in office, industrial and retail properties. Vornado Realty Trust is based in New York, New York.
Advisors' Opinion:- [By Robert Hsu]
Vornado Realty Trust (NYSE: VNO) is a traditional REIT.
Unlike mortgage REITs, Vornado actually invests directly in prime real estate properties such as office buildings, and the rents from these properties are what Vornado uses to generate income for unitholders.
Hot Rising Companies To Watch For 2014: Radio One Inc.(ROIAK)
Radio One, Inc., together with its subsidiaries, operates as an urban-oriented multi-media company in the United States. It engages in the radio broadcasting operation that primarily targets African-American and urban listeners. As of December 31, 2011, the company owned and operated 54 broadcast stations located in 16 urban markets. It also operates an African-American targeted cable television network and Tom Joyner Morning Show; and owns online platform serving the African-American community through social content, news, information, and entertainment, as well as operates various online social networking Websites, including BlackPlanet, MiGente, and Asian Avenue. The company was founded in 1980 and is based in Lanham, Maryland.
Advisors' Opinion:- [By Roberto Pedone]
Radio One (ROIAK) is a multimedia company that primarily targets African-American and urban consumers. This stock closed up 5.8% to $2.35 in Thursday's trading session.
Thursday's Range: $2.21-$2.40
52-Week Range: $0.68-$2.66
Thursday's Volume: 258,000
Three-Month Average Volume: 112,595From a technical perspective, ROIAK ripped higher here back above its 50-day moving average of $2.27 with above-average volume. This stock recently formed a triple bottom chart pattern at $2.10, $2.11 and $2.07. Following that bottom, shares of ROIAK have started bounce sharply higher and move within range of triggering a major breakout trade. That trade will hit if ROIAK can manage to take out some near-term overhead resistance levels at $2.46 to its 52-week high at $2.66 with high volume.
Traders should now look for long-biased trades in ROIAK as long as it's trending above some near-term support levels at $2.10 to $2.07 and then once it sustains a move or close above those breakout levels with volume that hits near or above 112,595 shares. If that breakout triggers soon, then ROIAK will set up to enter new 52-week-high territory above $2.66, which is bullish technical price action. Some possible upside targets off that breakout are $3 to $4.
Hot Rising Companies To Watch For 2014: Aviv REIT Inc (AVIV)
Aviv REIT, Inc., incorporated on July 30, 2010, is a self-administered real estate investment trust (REIT) , specializing in the ownership and triple-net leasing of post-acute and long-term cares skilled nursing facilities (SNF). The Company generates its cash rental stream by triple-net leasing its properties to third-party operators , including for all operating costs and expenses related to the property, maintenance and repair obligations and other required capital expenditures. The Company owns 316 properties that are triple-net leased to 38 operators in 28 states.
In May 2014, the Company acquired eight post-acute and long-term care skilled nursing facilities in California and Texas. In June 2014, Aviv REIT Inc acquired a post-acute and long-term care skilled nursing facility (SNF) in Kentucky. In July 2014, Aviv REIT Inc acquired two assisted living facilities (ALFs) and one post-acute and long-term care skilled nursing facility (SNF). Effective September 03, 2014, Aviv REIT Inc acquired four nursing facilities.
Advisors' Opinion:- [By Jayson Derrick]
Aviv REIT (NYSE: AVIV) has agreed to sell itself to Omega Healthcare Investors (NYSE: OHI) for $3 billion, or $34.97 per share. Omega Healthcare expects the deal to be accretive to its FFO and FAD in 2015. Shares of Aviv REIT hit new 52-week highs of $34.71 before closing the day at $33.73, up 12.06 percent. Shares of Omega Healthcare lost 1.78 percent, closinga t $38.16.
No comments:
Post a Comment